Supplementary Figure S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Akihito Kawazoe; Noboru Yamamoto; Naotoshi Sugimoto; Hisato Kawakami; Takashi Oshima; Kensei Yamaguchi; Kaori Hino; Motohiro Hirao; Yukinori Kurokawa; Takeshi Kawakami; Masahiro Tsuda; Hiroki Hara; Shota Kaname; Daiko Matsuoka; Yohei Otake; Keisuke Yasuda; Takao Takase; Shuya Takashima; Taro Semba; Kei Muro

doi:10.1158/1078-0432.25515819

Abstract

Supplementary Fig S3. Percent change in biomarkers at C1D8 (A) and C2D8 (B), pharmacodynamic changes in plasma biomarkers from C1D1 (C), and dichotomized analysis of plasma biomarker levels and PFS (D)

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kawazoe et al. (2024) studied this question.

synapsesocial.com/papers/68e712deb6db64358768c0e7 https://doi.org/10.1158/1078-0432.25515819

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Abstract

Discussion

Cite This Study

Supplementary Figure S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers